Follow us...

 

Search News Archives

News Channels

 

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

Novel Microfluidic Platform for Cancer Research

publication date: Feb 21, 2018
 | 
author/source: AMS Biotechnology (Europe) Ltd

Novel-Microfluidic-Platform-Cancer-Research

AMSBIO, a transatlantic life sciences company, and the University of Strathclyde (Glasgow, UK) have pioneered a multidisciplinary approach combining expertise in microfluidics and 3D culture to develop a novel microfluidic platform for cancer research.

The new platform combines microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids to enable formation and long-term culture of 3D multicellular tumors / organoids for drug screening and individualized chemosensitivity testing. Extensive testing shows that micro sizing drug-cell interactions reduces cost of experiments significantly as well as increasing productivity as it enables more experiments to be done on the same platform at the same time.

The microfluidic platform delivers precise control over the cellular microenvironment and beneficially through miniaturization, maximizes use of precious limited human cancer samples. Developed using leading-edge microsystem engineering, the platform delivers high-throughput analysis and is fully compatible with automated robotic dispensing systems. To enable customized data analysis of the results from the microfluidic platform, our academic team has also developed a suite of easy-to-use software.

The new microfluidic platform shows great promise to provide a cost-effective approach to applications including high-throughput drug screening and analysis and bioassays to assess spheroid function and morphology. In the area of personalized medicine, it is highly pertinent to not only predict the drug response at early time points during the therapy, but also to be able to identify the optimal drug combination for an individual patient. Within the scope of personalized medicine, this technology presents immense possibilities for testing patient-derived multicellular tumor spheroids/organoids (comprising cancer cells, stromal cells, cancer stem cells and/or immune cells) for disease/biomarker-oriented drug activity and profiling using single- and pair-wise standard/targeted drug combinations.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.


more news from amsbio



If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners